Daily Cardiology Research Analysis
Analyzed 99 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today: a randomized TRISCEND II analysis shows near-elimination of tricuspid regurgitation with transcatheter replacement and favorable right-heart remodeling; a large SCAPIS cohort links elevated lipoprotein(a) to higher coronary plaque burden and events, largely mediated by atherosclerosis; and a meta-analysis finds SGLT2 inhibitors after acute myocardial infarction in non-diabetics reduce first heart failure hospitalization and improve LVEF.
Research Themes
- Transcatheter tricuspid valve replacement and right-heart remodeling
- Lipoprotein(a), coronary atherosclerosis burden, and event risk
- SGLT2 inhibitors after acute myocardial infarction in non-diabetics
Selected Articles
1. TRISCEND II: Effect of Transcatheter Tricuspid Valve Replacement on Echocardiographic Measures of Right Heart Remodeling and Function.
In TRISCEND II, transcatheter tricuspid valve replacement with the EVOQUE system reduced tricuspid regurgitation to mild in >95% at discharge and sustained to 1 year, with significant decreases in IVC diameter and right ventricular size. Despite expected reductions in RV systolic function from preload unloading, RV stroke volume and cardiac output increased, indicating improved forward flow compared with medical therapy.
Impact: This rigorously conducted randomized trial provides mechanistic and hemodynamic evidence that near-elimination of tricuspid regurgitation via TTVR yields right-heart reverse remodeling and improved forward flow.
Clinical Implications: For patients with severe symptomatic tricuspid regurgitation, TTVR can achieve durable TR reduction with reduced venous congestion and increased forward stroke volume, supporting its use in appropriately selected patients and informing expectations for RV functional changes post-procedure.
Key Findings
- At discharge and sustained to 1 year, >95% of TTVR patients had mild tricuspid regurgitation versus 2.3% in controls at 1 year.
- Inferior vena cava diameter decreased significantly more after TTVR, indicating reduced venous congestion.
- Right ventricular diastolic size improved, with expected reductions in RV systolic function consistent with preload unloading.
- RV stroke volume and cardiac output increased significantly after TTVR but not with medical therapy.
Methodological Strengths
- Randomized controlled design with independent echocardiographic core laboratory assessment
- Prospective multicenter cohort with paired analyses from baseline to 1 year
Limitations
- Echocardiographic outcomes rather than hard clinical endpoints at 1 year
- Generalizability may be limited to trial-eligible patients and early post-approval experience
Future Directions: Longer-term follow-up comparing clinical outcomes (mortality, HF hospitalization) and right-heart functional trajectories, and refining patient selection and peri-procedural management strategies.
BACKGROUND: The TRISCEND II (EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device) trial demonstrated clinical benefits for transcatheter tricuspid valve replacement (TTVR) with the EVOQUE system over medical therapy for the primary safety and effectiveness endpoint to 1 year. OBJECTIVES: The authors report echocardiographic outcomes at 1 year for the randomized cohort and evaluate hemodynamic and structural changes. METHODS: The multicenter, prospective TRISCEND II trial enrolled 400 patients with severe, symptomatic tricuspid regurgitation (TR) and randomized them in a 2:1 ratio to TTVR (n = 267) or medical therapy (control) (n = 133). The secondary echocardiographic endpoint was reduction in TR severity from baseline to discharge. Echocardiograms were evaluated by an independent echocardiographic core laboratory. RESULTS: All patients had severe TR at baseline; at discharge, 95.5% of patients who underwent TTVR had mild TR. On paired analysis from baseline to 1 year, 95.3% of patients who underwent TTVR and 2.3% of control patients achieved mild TR. Between baseline and 1 year, the mean inferior vena cava diameter decreased significantly more for patients who underwent TTVR (normal breathing P < 0.001, forced inhalation P = 0.038). Patients who underwent TTVR experienced greater improvements in diastolic right ventricular (RV) size (P < 0.05) and larger decreases in RV systolic function (P < 0.001), consistent with reduced preload from TR reduction. RV stroke volume and cardiac output increased significantly in patients who underwent TTVR (P < 0.001) but not in control patients. CONCLUSIONS: One-year echocardiographic outcomes from the TRISCEND II trial demonstrated that near elimination of TR following TTVR is associated with reduced venous congestion, RV reverse remodeling, and significant improvements in forward stroke volume and cardiac output.
2. Association of Lipoprotein(a) With Coronary Atherosclerosis and Cardiovascular Events: Findings From the SCAPIS Cohort.
In a population-based cohort of 28,529 adults, high Lp(a) (present in 14%) was linked to both severe coronary atherosclerosis on CCTA and increased coronary events, with mediation analyses indicating that excess risk is largely explained by greater plaque burden. High Lp(a) shifted atherosclerosis onset 2–3 years earlier and accounted for 5–10% of severe atherosclerosis and ~7% of coronary events.
Impact: This study integrates large-scale coronary imaging and events with mediation analysis, clarifying that Lp(a)-related risk operates predominantly through increased atherosclerotic burden.
Clinical Implications: Supports routine Lp(a) measurement and selective coronary imaging for risk stratification; informs the rationale for Lp(a)-lowering therapies and surveillance strategies targeting atherosclerosis burden.
Key Findings
- High Lp(a) was present in 14% of participants.
- High Lp(a) associated with severe/extensive coronary atherosclerosis on CCTA (OR 1.38, 95% CI 1.21–1.57).
- High Lp(a) associated with increased coronary events (HR 1.54, 95% CI 1.18–2.0).
- Mediation analyses showed Lp(a)-event association is largely explained by higher atherosclerotic burden (P<0.0001).
- High Lp(a) advanced atherosclerosis by 2–3 years; PAF ~5–10% for severe atherosclerosis and ~7% for coronary events.
Methodological Strengths
- Large, population-based cohort with extensive CCTA imaging
- Stratified, adjusted, and mediation analyses to dissect causal pathways
Limitations
- Observational design cannot establish causality definitively
- Potential residual confounding and limited generalizability outside the study population
Future Directions: Evaluate Lp(a)-lowering therapies on plaque burden and events; refine imaging-based risk stratification thresholds for high Lp(a) individuals.
BACKGROUND: High lipoprotein(a) (Lp[a]) associates with elevated coronary heart disease event risk, but it remains uncertain whether this excess risk can be explained by increased coronary plaque burden. OBJECTIVES: This study aims to determine whether Lp(a)-related excess cardiovascular risk in the general population is primarily explained by increased coronary atherosclerosis or by additional plaque vulnerability-related effects. METHODS: This study included 28,529 middle-aged individuals from the SCAPIS (Swedish CArdioPulmonary bioImage Study), a population-based cohort. Coronary atherosclerosis was assessed using coronary computed tomography angiography in 25,916 participants. Incident coronary events, defined as fatal or nonfatal myocardial infarction, were ascertained over a median follow-up of 7.8 years. RESULTS: High Lp(a) was present in 14% of participants and associated with severe/extensive coronary atherosclerosis (Segment Involvement Score >4; OR: 1.38; 95% CI: 1.21-1.57) and coronary events (HR: 1.54; 95% CI: 1.18-2.0). Stratified, adjusted, and mediation analyses consistently suggested that the association between Lp(a) and coronary event risk is largely explained by greater atherosclerotic burden (P for mediation <0.0001). Individuals with high Lp(a) developed atherosclerosis 2 to 3 years earlier and the population-attributable fraction of Lp(a) was 5% to 10% for severe atherosclerosis and around 7% for coronary events. CONCLUSION: The findings suggest that Lp(a) increases coronary event risk primarily by driving a higher burden of atherosclerosis and that high Lp(a) accounts for 5% to 10% of total coronary disease burden in the population. These results support broad Lp(a) measurements and the use of coronary imaging for risk stratification in individuals with high Lp(a).
3. Sodium-Glucose Cotransporter-2 Inhibitors Following Acute Myocardial Infarction in Patients Without Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Across five RCTs (n=9,135) in non-diabetic post-AMI patients without HF, SGLT2 inhibitors reduced first HF hospitalization (RR 0.74), improved LVEF (MD 2.08), and lowered NT-proBNP, without affecting all-cause mortality or the HF+all-cause mortality composite.
Impact: Synthesizing RCT evidence in a previously understudied population, this meta-analysis suggests SGLT2 inhibitors confer early post-MI benefits independent of diabetes or baseline HF.
Clinical Implications: SGLT2 inhibitors may be considered for early initiation after AMI in selected non-diabetic patients to reduce HF hospitalization and support LV recovery, pending confirmatory trials with mortality endpoints.
Key Findings
- Five RCTs (n=9,135) showed SGLT2 inhibitors reduced first HF hospitalization (RR 0.74, p=0.02).
- LVEF improved by a mean difference of 2.08 percentage points (p=0.002).
- NT-proBNP levels were significantly reduced (MD 12.81; p<0.0001).
- No significant differences in all-cause mortality or the composite of first HF hospitalization plus all-cause mortality.
Methodological Strengths
- Random-effects meta-analysis pooling only randomized controlled trials
- Comprehensive database search through 2025 with standardized effect estimates (RR, MD) and 95% CIs
Limitations
- Heterogeneity in trial designs, timing of initiation, and follow-up duration
- No mortality benefit observed; applicability may be limited to non-diabetic, non-HF AMI populations studied
Future Directions: Dedicated, adequately powered trials to test mortality and rehospitalization endpoints, optimal timing, and duration of SGLT2i after AMI in broader populations.
BACKGROUND: Sodium-glucose transporter 2 (SGLT2) inhibitors have shown significant cardiovascular benefits in heart failure (HF) patients with diabetes mellitus or chronic kidney disease. However, their safety and efficacy in non-diabetic patients without HF presenting with acute myocardial infarction (AMI) remain understudied. METHODS: Databases including MEDLINE, Scopus, Cochrane Library, and ClinicalTrials.gov were queried through August 2025 to identify randomized controlled trials (RCTs). Data were pooled using a random-effects model using risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). RESULTS: Five RCTs involving 9,135 patients (SGLT2i: 4,581 and placebo: 4,554) were included. On pooled analysis, SGLT2 inhibitors were associated with significantly reduced first HF hospitalization (RR: 0.74, p=0.02), improved LVEF (MD: 2.08; p=0.002), and reduced NT-proBNP levels (MD: 12.81; p < 0.0001). No significant differences were noted in all-cause mortality and the composite of first HF hospitalization with all-cause mortality. CONCLUSION: In non-diabetic patients without HF, SGLT2 inhibitors significantly reduce the first HF hospitalization and improve LVEF following AMI. The findings of this meta-analysis suggest that future research should evaluate the cardiovascular benefits of SGLT2 inhibitors in this patient population.